Yüklüyor......
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus trastuzumab as neoadjuvant treatment for patients with HER2-positive breast cancer (Z1041): a randomised, controlled, phase 3 trial
BACKGROUND: Neoadjuvant chemotherapy with trastuzumab for patients with HER2-positive breast cancer can produce a pathological complete response in the breast in 30–65% of patients. We investigated the effect of the timing of trastuzumab administration with anthracycline and taxane neoadjuvant chemo...
Kaydedildi:
| Asıl Yazarlar: | , , , , , , , , , , |
|---|---|
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
2013
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4176878/ https://ncbi.nlm.nih.gov/pubmed/24239210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(13)70502-3 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|